Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

eXoZymes, Inc. EXOZ NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

eXoZymes, Inc. (EXOZ) is a Biotechnology company in the Healthcare sector, currently trading at $11.00. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: EXOZ trades at a trailing Price-to-Earnings (P/E) of -9.8 (S&P 500 average ~25).

Net income is $9M (loss), growing at -96.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $3M equity (Debt-to-Equity (D/E) ratio 0.37, conservative). Current ratio is 2.51 (strong liquidity). Debt-to-assets is 20.8%. Total assets: $6M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

EXOZ SharesGrow Score Overview

48/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EXOZ

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
EXOZ: +0%/yr revenue is, -96.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet EXOZ: Debt-to-Equity (D/E) ratio 0.37 (conservative), Current ratio is 2.51 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
EXOZ: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range7.08-18.4
Volume7.62K
Avg Volume (30D)4.34K
Market Cap$93.27M
Beta (1Y)2.55
Share Statistics
EPS (TTM)-1.09
Shares Outstanding$8.38M
IPO Date2024-11-13
Employees31
CEOMichael Heltzen
Financial Highlights & Ratios
EBITDA$-9.43M
Net Income$-9.16M
Operating Income$-9.72M
Total Cash$3.04M
Total Debt$1.24M
Net Debt$-1.8M
Total Assets$5.97M
Price / Earnings (P/E)-10.1
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS4618741098

Price Chart

Track all markets on TradingView
EXOZ
eXoZymes, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
7.08 52WK RANGE 18.40

People Also View

GLSI
GLSI
Greenwich LifeSciences, Inc.
$26.02
-5.35%
 SRZN
SRZN
Surrozen, Inc.
$31.07
+4.05%
 ONCY
ONCY
Oncolytics Biotech Inc.
$1.02
-2.86%
 TLSA
TLSA
Tiziana Life Sciences Ltd
$1.29
+12.17%
 ESLA
ESLA
Estrella Immunopharma, Inc.
$1.73
-1.14%
 CGTX
CGTX
Cognition Therapeutics, Inc.
$0.98
+0.10%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 ATOS
ATOS
Atossa Therapeutics, Inc.
$5.35
+0.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message